PURPOSE: To generate and characterize a constitutively active, RPE-specific, cre-expressing transgenic mouse line. This line can be used to create RPE-specific knockouts by crossing with mice harboring loxP-flanked (floxed) genes. METHODS: A transgene construct was assembled with the BEST1 promoter driving cre expression. Transgenic mice were generated on a C57BL/6 background. Cre expression was assessed by immunofluorescence and Western blot analysis. Cre enzymatic activity was tested by crossing to three lines with floxed DNA regions and detecting deletion of the intervening sequences or through histochemical detection of lacZ activity. Potential cre-mediated toxicity was assessed by retinal histology up to 24 months of age and by electroretinography. RESULTS: The BEST1-cre line with expression in the highest percentage of RPE cells displayed a patchy mosaic expression pattern, with 50% to 90% of RPE cells expressing cre. In mice outcrossed to a mixed B6/129 background, expression was consistently found in 90% of RPE cells. Within the eye, only the RPE cells were immunoreactive with an anti-cre antibody. Maximum cre expression quantified by Western blot analysis occurred at P28. Crosses with three lines containing floxed sequences revealed RPE-specific cre activity in the eye and extraocular expression limited to the testes. Histology and electroretinography showed no cre-mediated RPE toxicity. CONCLUSIONS: This BEST1-cre transgenic line enables generation of RPE-specific knockout mice. The mosaic expression pattern provides an internal control; the non-cre-expressing RPE cells continue to express the floxed genes. These mice should facilitate study of the multifunctional RPE and the generation of mouse models of human retinal disease.
PURPOSE: To generate and characterize a constitutively active, RPE-specific, cre-expressing transgenicmouse line. This line can be used to create RPE-specific knockouts by crossing with mice harboring loxP-flanked (floxed) genes. METHODS: A transgene construct was assembled with the BEST1 promoter driving cre expression. Transgenic mice were generated on a C57BL/6 background. Cre expression was assessed by immunofluorescence and Western blot analysis. Cre enzymatic activity was tested by crossing to three lines with floxed DNA regions and detecting deletion of the intervening sequences or through histochemical detection of lacZ activity. Potential cre-mediated toxicity was assessed by retinal histology up to 24 months of age and by electroretinography. RESULTS: The BEST1-cre line with expression in the highest percentage of RPE cells displayed a patchy mosaic expression pattern, with 50% to 90% of RPE cells expressing cre. In mice outcrossed to a mixed B6/129 background, expression was consistently found in 90% of RPE cells. Within the eye, only the RPE cells were immunoreactive with an anti-cre antibody. Maximum cre expression quantified by Western blot analysis occurred at P28. Crosses with three lines containing floxed sequences revealed RPE-specific cre activity in the eye and extraocular expression limited to the testes. Histology and electroretinography showed no cre-mediated RPE toxicity. CONCLUSIONS: This BEST1-cre transgenic line enables generation of RPE-specific knockout mice. The mosaic expression pattern provides an internal control; the non-cre-expressing RPE cells continue to express the floxed genes. These mice should facilitate study of the multifunctional RPE and the generation of mouse models of humanretinal disease.
Authors: Mikiro Mori; Daniel Metzger; Jean-Marie Garnier; Pierre Chambon; Manuel Mark Journal: Invest Ophthalmol Vis Sci Date: 2002-05 Impact factor: 4.799
Authors: Chen Zhao; Douglas Yasumura; Xiyan Li; Michael Matthes; Marcia Lloyd; Gregory Nielsen; Kelly Ahern; Michael Snyder; Dean Bok; Joshua L Dunaief; Matthew M LaVail; Douglas Vollrath Journal: J Clin Invest Date: 2010-12-06 Impact factor: 14.808
Authors: Mei Jiang; Antonio E Paniagua; Stefanie Volland; Hongxing Wang; Adarsh Balaji; David G Li; Vanda S Lopes; Barry L Burgess; David S Williams Journal: J Cell Sci Date: 2020-08-04 Impact factor: 5.285
Authors: Aristomenis Thanos; Yuki Morizane; Yusuke Murakami; Andrea Giani; Dimosthenis Mantopoulos; Maki Kayama; Mi In Roh; Norman Michaud; Basil Pawlyk; Michael Sandberg; Lucy H Young; Joan W Miller; Demetrios G Vavvas Journal: Am J Pathol Date: 2012-03-17 Impact factor: 4.307
Authors: Natalie Wolkow; Delu Song; Ying Song; Sally Chu; Majda Hadziahmetovic; Jennifer C Lee; Jared Iacovelli; Steven Grieco; Joshua L Dunaief Journal: Am J Pathol Date: 2012-02-17 Impact factor: 4.307